ALNY - Alnylam Pharmaceuticals Inc Stock Analysis
Alnylam Pharmaceuticals Inc (ALNY) is a publicly traded company listed on the NASD. It operates in the Biotechnology industry, part of the broader Healthcare sector. The company has a market capitalization of 42.58B, generates annual revenue of 3.21B, and reports net income of 43.56M. As of the latest data, the stock is trading at 322.28 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is trading at a high valuation compared to the market average, suggesting investor optimism or growth expectations. The PEG ratio is below 1, which may indicate the stock is undervalued relative to its growth potential. The company is highly leveraged, which may pose risks during economic downturns or periods of rising interest rates. This stock does not currently pay a dividend. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at Hold (3.97), indicating current market sentiment. Institutional ownership is reported at 100.64%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 19.81%, trading within a 52-week range of 205.87 - 495.55.
ALNY - Alnylam Pharmaceuticals Inc
322.28
Analyst Consensus
Hold 3.97
ALNY – Analyst Rating Summary
- Strong Buy: 8
- Buy: 19
- Hold: 9
- Sell: 0
- Strong Sell: 0
- Total Analysts: 36
| Index: | NDX | P/E: | 1340.60 | EPS (ttm): | 0.24 | Insider Own: | 1.94% | Shs Outstand: | 131.79M | Perf Week: | -8.43% |
| Market Cap: | 42.58B | Forward P/E: | 45.17 | EPS next Y: | 7.14 | Insider Trans: | -5.83% | Shs Float: | 129.55M | Perf Month: | -13.11% |
| Income(ttm): | 43.56M | PEG: | - | EPS next Q: | 1.16 | Inst Own: | 100.64% | Short Float: | 4.08% | Perf Quarter: | -27.04% |
| Revenue(ttm): | 3.21B | P/S: | 13.26 | EPS this Y: | 213.03% | Inst Trans: | 2.76% | Short Ratio: | 3.58 | Perf Half Y: | -25.04% |
| Book/sh: | 1.77 | P/B: | 181.59 | EPS next Y: | 189.56% | ROA: | 0.96% | Short Interest: | 5.28M | Perf Year: | 19.81% |
| Cash/sh: | 20.62 | P/C: | 15.63 | EPS next 5Y: | - | ROE: | 32.73% | 52W Range: | 205.87 - 495.55 | Perf YTD: | -18.95% |
| Dividend Est.: | - | P/FCF: | 192.35 | EPS past 3/5Y: | 32.86% 23.11% | ROIC: | 1.53% | 52W High: | 495.55 -34.97% | Beta: | 0.36 |
| Dividend TTM: | - | Quick Ratio: | 2.49 | Sales past 3/5Y: | 38.61% 59.21% | Gross Margin: | 83.90% | 52W Low: | 205.87 56.55% | Perf 5Y: | 94.87% |
| Dividend Ex-Date: | - | Current Ratio: | 2.54 | EPS Y/Y TTM: | 111.86% | Oper. Margin: | 8.25% | RSI (14): | 29.38 | Volatility: | 3.88% 3.39% |
| Employees: | 2230 | Debt/Eq: | 11.86 | Sales Y/Y TTM: | 53.24% | Profit Margin: | 1.36% | Recom: | 1.77 | Target Price: | 484.71 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 11.17 | EPS Q/Q: | 312.06% | Payout: | - | Rel Volume: | 1.07 | Prev Close: | 322.98 |
| Sales Surprise: | 30.19% | EPS Surprise: | 227.99% | Sales Q/Q: | 149.35% | Earnings: | Feb 12 BMO | Avg Volume: | 1.48M | Price: | 322.28 |
| SMA20: | -7.29% | SMA50: | -16.36% | SMA200: | -16.65% | Undervalued: 50.4% | Volume: | 1,579,317 | Change: | -0.22% | |
Graham Classic formula value: 1.83
(P/E=8 * 1g) Min value: 1.72
(current P/E * 2g) Max value: 288.91
Average value: 97.49
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.